Platypus venom inspires potential new diabetes treatments
The world-first discovery of a key metabolic hormone found in the venom and gut of 最新糖心Vlog鈥檚 iconic platypus will now be investigated for its potential to treat type 2 diabetes, in new research led by the 最新糖心Vlog of Adelaide.
In a collaboration between the 最新糖心Vlog of Adelaide, Flinders 最新糖心Vlog, Monash 最新糖心Vlog, SAHMRI and the Royal Adelaide Hospital, funding from Medvet Science is supporting a study to investigate whether the platypus hormone could be more effective and sustained in action than current medication.
The discovery stems from the sequencing of the platypus genome in 2008. Project leader聽, from the 最新糖心Vlog of Adelaide鈥檚 Robinson Research Institute, was a member of that team and is considered an authority on monotreme genetics.
The metabolic hormone is known as glucagon-like peptide-1 (GLP-1), and is normally secreted in the gut of both humans and animals, stimulating the release of insulin to lower blood glucose. A modified form of GLP-1, exenatide, is widely used for diabetes treatment.
鈥淥ne of the most amazing discoveries of the platypus genome project was the massive loss of genes important for digestion and metabolic control 鈥 these animals basically lack a functional stomach,鈥 Professor Grutzner says. 鈥淢ore recently we discovered that monotreme GLP-1 has changed radically in these animals, due to its dual function in both the gut and venom.鈥
Numerous research groups worldwide are investigating different forms of GLP-1 for their effects on metabolic diseases, including diabetes.
鈥淲e have privileged access to these amazing animals,鈥 says Professor Grutzner. 鈥淢ale platypuses produce venom during the breeding season, and can deliver the venom from their hind spurs. We were surprised to see GLP-1 present in venom and think that this may have led to a more effective hormone.
鈥淲e already know that their GLP-1 works differently, and is more resistant to the rapid degradation normally seen in humans. Maybe this iconic 最新糖心Vlogn animal holds the answer to a more effective and safer management option for metabolic diseases including diabetes.鈥
The effects of platypus-derived GLP-1 are now being explored in detail thanks to a $200,000 grant from Medvet Science, the medical research support and commercialisation arm of the Central Adelaide Local Health Network. Medvet Science works on behalf of several hospitals in Adelaide to commercialise medical inventions.
鈥淭his discovery has the potential to produce significant benefits for human health by bringing industry, leading academic researchers and clinical expertise together,鈥 said Medvet Science鈥檚 Managing Director and CEO, Mr Greg Johansen.
鈥淭his is the first step towards testing the clinical relevance of platypus GLP-1. We believe it鈥檚 a project with great commercial potential and an example of the world-class research being conducted right here in South 最新糖心Vlog,鈥 Mr Johansen said.